| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Krishnan Krish S | President and CEO, Director, 10%+ Owner | C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH | /s/ Krish S. Krishnan | 06 Mar 2026 | 0001298709 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | KRYS | Common Stock | Sale | $124,282 | -483 | -0.03% | $257.31 | 1,499,770 | 04 Mar 2026 | Direct | F1, F2, F3 |
| transaction | KRYS | Common Stock | Sale | $121,438 | -470 | -0.03% | $258.38 | 1,499,300 | 04 Mar 2026 | Direct | F4 |
| transaction | KRYS | Common Stock | Sale | $357,838 | -1,377 | -0.09% | $259.87 | 1,497,923 | 04 Mar 2026 | Direct | F5 |
| transaction | KRYS | Common Stock | Sale | $814,802 | -3,128 | -0.21% | $260.49 | 1,494,795 | 04 Mar 2026 | Direct | F6 |
| transaction | KRYS | Common Stock | Sale | $774,289 | -2,962 | -0.2% | $261.41 | 1,491,833 | 04 Mar 2026 | Direct | F7 |
| transaction | KRYS | Common Stock | Sale | $624,619 | -2,380 | -0.16% | $262.44 | 1,489,453 | 04 Mar 2026 | Direct | F8 |
| transaction | KRYS | Common Stock | Sale | $538,741 | -2,043 | -0.14% | $263.70 | 1,487,410 | 04 Mar 2026 | Direct | F9 |
| transaction | KRYS | Common Stock | Sale | $2,330,151 | -8,798 | -0.59% | $264.85 | 1,478,612 | 04 Mar 2026 | Direct | F10 |
| transaction | KRYS | Common Stock | Sale | $647,773 | -2,439 | -0.16% | $265.59 | 1,476,173 | 04 Mar 2026 | Direct | F11 |
| transaction | KRYS | Common Stock | Sale | $245,231 | -920 | -0.06% | $266.56 | 1,475,253 | 04 Mar 2026 | Direct | F12 |
| holding | KRYS | Common Stock | 90,000 | 04 Mar 2026 | By Krishnan Spousal Trust | ||||||
| holding | KRYS | Common Stock | 50,000 | 04 Mar 2026 | By Krishnan Family Trust | F13 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | The Reporting Person may be deemed to beneficially own shares of the Issuer's common stock directly owned by the Reporting Person's spouse, Suma M. Krishnan. Such shares and transactions by the Reporting Person's spouse are not included in this Form 4, as they are being reported separately on a Form 4 filed by his spouse. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. |
| F2 | The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025. The Rule 10b5-1 trading plan started on December 4, 2025 and will terminate on December 4, 2026, or earlier in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan. |
| F3 | The transaction was executed in multiple trades ranging from $256.81 to $257.75. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| F4 | The transaction was executed in multiple trades ranging from $257.89 to $258.765. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| F5 | The transaction was executed in multiple trades ranging from $259.07 to $260.06. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| F6 | The transaction was executed in multiple trades ranging from $260.07 to $261.06. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| F7 | The transaction was executed in multiple trades ranging from $261.07 to $262.04. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| F8 | The transaction was executed in multiple trades ranging from $262.08 to $263. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| F9 | The transaction was executed in multiple trades ranging from $263.19 to $264.1. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| F10 | The transaction was executed in multiple trades ranging from $264.2 to $265.19. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| F11 | The transaction was executed in multiple trades ranging from $265.235 to $266.19. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| F12 | The transaction was executed in multiple trades ranging from $266.36 to $266.93. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| F13 | Directly beneficially owned by the Krishnan Family Trust. The Reporting Person and his spouse are each joint beneficial owners of the trust with joint voting and investment control, and holdings and transactions by the Krishnan Family Trust are also reflected on the separate Form 4 filed by his spouse. |